|Bid||0.00 x 30000|
|Ask||0.00 x 30000|
|Day's Range||186.35 - 186.35|
|52 Week Range||110.90 - 192.95|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||33.08|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||2.79 (1.50%)|
|Ex-Dividend Date||May 13, 2021|
|1y Target Est||N/A|
Biogen (NASDAQ: BIIB) stock skyrocketed after its Alzheimer's disease drug Aduhelm won U.S. Food and Drug Administration (FDA) approval. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss two stocks that could also be winners along with Biogen.
In May, the Biden administration backed the idea of waiving intellectual property protections for COVID-19 vaccines. In a new interview, pharmaceutical giant Eli Lilly CEO David Ricks weighed in says “this is a counterproductive move.”
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.